Targeted Secretion Inhibition: Applications in Oncology, Endocrinology, and Neurology/Pain
Offered by Harvard Catalyst’s Translational Innovator, this pilot funding opportunity provided up to $50,000 in funding plus access to Ipsen’s Targeted Secretion Inhibitor (TSI) technology platform to expand the clinical potential for this novel class of biopharmaceuticals. TSIs can inhibit cellular secretion for prolonged periods and may be suitable for use in a wide range of diseases where inhibition of cellular secretion could provide new therapeutic potential.
This pilot grant opportunity promoted the design, development, and evaluation of novel TSIs for their potential clinical application in cancer, endocrine, neurological disorders, or pain. A critical feature of this research program was Ipsen’s commitment to provide any awardees, who may require it, with scientific and technical support to design and develop project-related TSIs. Successful applicants did not necessarily need to be able to generate the TSI molecular constructs for their proposed work.
Pilot grant proposals described innovative and translational research projects that, if successful, could provide new insights into the application of TSI technologies to inform:
- Clinical decisions
- Disease detection, causation, progression, or treatment
- The development of new therapeutics, diagnostics, or clinically informative biomarkers
Proposals should focus on applications in the fields of oncology, endocrinology, or neurology/pain.
Five pilot grants were awarded in amounts of up to $50,000 for each one-year project – starting February 1, 2018